VIR - Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD's The Liver Meeting® 2023 | Benzinga
SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023. These include seven poster presentations, one of which is a late-breaking poster, and one late-breaking oral presentation.
"Results from our ongoing studies underscore the tremendous progress we are making toward addressing the needs of the millions of people living with chronic hepatitis B and chronic hepatitis delta," said Phil Pang, M.D., Ph.D., Vir's Executive Vice President, Chief Medical Officer and Interim Head of Research. "We are eager to present additional data from our multiple ongoing trials at AASLD, especially the data from two late-breaking presentations on the potential clinical impact that VIR-3434 and VIR-2218 could have for both CHB and CHD patients."
| Presentations |
| • |
| Title: VIR-2218 and VIR-3434 therapy is efficacious in preclinical models of hepatitis delta virus infection (Poster #1257-C) |
| Session: Poster Session 1 |
| Date: Friday, November 10 |
| Time: 12:00 p.m. ET |
| Presenter: Jiayi Zhou, MBA, Senior Research Associate, Virology at Vir Biotechnology |
| • |
| Title: Pharmacokinetics and safety of VIR-2218 monotherapy in adult cirrhotic participants with moderate hepatic impairment (Poster #1480-C) |
| Session: Poster Session 1 |
| Date: Friday, November 10 |
| Time: 12:00 p.m. ET |
| Presenter: Sneha V. Gupta, Ph.D., Director, Clinical Pharmacology at Vir Biotechnology |
| • |
| Title: Initial evaluation of immune complex binding in a phase 1 safety and tolerability study of chronic HBV participants given a single dose of VIR-3434 (Poster #1511-C) |
| Session: Poster Session 1 |